Treatment of Ebola Virus Disease with Bacterial Co-infection in Adults with Severe Disease
Clinical scenario
Adult patients with severe Ebola virus disease may develop concurrent bacterial co-infection, a complication that requires antimicrobial intervention alongside management of the primary viral illness.
Adult
Bacterial co-infection
Severe disease
Why this matters
In severe Ebola virus disease, bacterial co-infection introduces an additional infectious burden that must be addressed with targeted antibiotic therapy. The suspected source of bacterial infection — whether systemic, neurological, or urinary — directly shapes the clinical approach.
Antibiotic approach — partial overview
Management centres on intravenous antibiotic therapy, with agent selection determined by the suspected focus of bacterial infection. Different clinical presentations — including suspected central nervous system involvement or specific systemic bacterial sources — call for distinct antibiotic choices and regimen adjustments.
Full regimen details, agent selection criteria, dosing, and duration are in the complete protocol →
References
- Severe disease: IV ceftriaxone 2 g once daily 5 days +/- IV metronidazole 500 mg three times/day (usually 7 days).
- If suspect bacterial meningitis, then give higher dose, ceftriaxone at 2 g twice daily.
- Adult: oral 500 mg twice daily (7–10 days for typhoid) or IV 400 mg twice daily (5 days).
View source ↗